Reset
Showing 6 of 6 academic articles

Global disparities in access to hepatitis C medicines before and during the early phase of the COVID-19 pandemic: an ARIMA-based interrupted time series analysis

Nick Bansback, Mina Tadrous, Marie Paul Nisingizwe, Michael R Law et al. • BMJ Public Health (2025)

Background The introduction of direct-acting antivirals (DAAs) has allowed countries to reduce the health and economic burden of hepatitis C virus (HCV). However, access to DAAs remains expensive and limited in many countries globally due t...

DOAJ Open Access (DOAJ) DOI: 10.1136/bmjph-2024-001340

C no more: a prospective single-arm study to evaluate the effectiveness of a nurse and peer-led mobile model of hepatitis C testing and treatment at community corrections offices

Samara Griffin, Timothy Papaluca, Jacinta A Holmes, Bridget Reid et al. • Health & Justice (2026)

Abstract Background The community corrections population in Australia shares similar risk factors for hepatitis C virus (HCV) infection with people incarcerated in prisons, but without access to prison-based testing and treatment. While hep...

DOAJ Open Access (DOAJ) DOI: 10.1186/s40352-026-00411-6

HCV-associated mixed cryoglobulinemia and b-cell non-Hodgkin's lymphoma - pathogenetically related problems

S Yu Milovanova, L V Lysenko (Kozlovskaya), L Yu Milovanova, N N Mrykhin et al. • Терапевтический архив (2018)

Hepatitis C virus (HCV) is a global population problem due to its high prevalence, usually late diagnosis, the difficulties of treatment. In the prognosis of patients with HCV not only hepatic, but increasingly frequent of extrahepatic HCV ...

DOAJ Open Access (DOAJ) DOI: 10.26442/terarkh2018906112-120

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China

Hui Jun Zhou, Jing Cao, Hui Shi, Nasheen Naidoo et al. • Frontiers in Public Health (2021)

Background: Hepatitis C virus (HCV) genotype 1 is the most prevalent HCV infection in China. Sofosbuvir-based direct antiviral agent (DAA) regimens are the current mainstays of treatment. Sofosbuvir/velpatasvir (SOF/VEL) and sofosbuvir/ledi...

DOAJ Open Access (DOAJ) DOI: 10.3389/fpubh.2021.779215

Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma

Zelin Tian, Chen Xu, Peijun Yang, Zhibin Lin et al. • Frontiers in Immunology (2022)

Hepatocellular carcinoma(HCC) is the sixth most common cancer in the world and is usually caused by viral hepatitis (HBV and HCV), alcoholic, and non-alcoholic fatty liver disease(NAFLD). Viral hepatitis accounts for 80% of HCC cases worldw...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2022.984728

Epidemiology of Hepatitis C Virus in Bangladeshi General Population

Mamun Al-Mahtab, Salimur Rahman, Fazal Karim, Graham Foster et al. • Bangabandhu Sheikh Mujib Medical University Journal (2009)

Background: Hepatitis C virus is encountered sporadically in Bangladesh. It results in a wide range liver diseases, with asymptomatic acute hepatitis rarely at one end to HCC at the other end of the spectrum. Methods: 1018 individuals of ...

DOAJ Open Access (DOAJ) DOI: 10.3329/bsmmuj.v2i1.3705